# Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors

> **NCT05139082** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 60 (estimated)

## Conditions studied

- Digestive System Tumors

## Interventions

- **DRUG:** TQB3616 capsules＋ TQB2450 injection

## Key facts

- **NCT ID:** NCT05139082
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-24
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05139082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05139082, "Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05139082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*